ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 168

Allopurinol Use Is Associated with a Decreased Risk of Myocardial Infarction

Lamiae Grimaldi-Bensouda1, Annick Alpérovitch2, Elodie Aubrun1, Nicolas Danchin3, Michel Rossignol4, Lucien Abenhaim5, Pascal Richette6 and PGRx MI Group7, 1LA-SER, Paris, France, 2Inserm U708-Neuroepidemiology, La Pitié-Salpêtrière Hospital, Paris, France, 3Coronary disease unit, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris and Paris-Descartes University, Paris, France, 4LA-SER, Centre for Risk Research, Montreal, Canada, 5LA-SER Europe Ltd, London, United Kingdom, 6Lariboisière Hospital, Paris, France, 7Paris, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: gout

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and the oxidative stress in the vasculature, which are known cardiovascular risk factors. However, the effects of XOI on major cardiac events such as myocardial infarction (MI) are unknown. The objective was to investigate whether XOI use is associated with a modified risk of myocardial infarction.

Methods: We used a matched case-control study comparing patients with first ever MI with controls. Cases were retrieved from a myocardial infarction registry consisting of 63 cardiology centers, whereas controls were selected from general practice settings. The association between XOI or colchicine use and MI was assessed by adjusted OR from conditional logistic regression.

Results: Data are from 2277 MI patients matched to 4849 controls. Allopurinol was by far the most frequent XOI taken by participants of this study. The adjusted OR (95% CI) for MI in allopurinol users was 0.75 (0.56-1.01), and it was 0.66 (0.49-0.89) using the whole pool of referents (n=8444). The effect of allopurinol persisted across subgroups by sex, presence of hypertension, and in ST-segment elevation MI patients. In contrast, colchicine use was not associated with a modified risk of MI: aOR= 1.17 (0.70-1.93).

Conclusion: Allopurinol, but not colchicine use, is associated with around a 30% reduction in the risk of myocardial infarction. Besides its urate lowering property, allopurinol might have a cardio protective effect.


Disclosure:

L. Grimaldi-Bensouda,
None;

A. Alpérovitch,
None;

E. Aubrun,
None;

N. Danchin,
None;

M. Rossignol,
None;

L. Abenhaim,
None;

P. Richette,
None;

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/allopurinol-use-is-associated-with-a-decreased-risk-of-myocardial-infarction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology